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Open access under CC BYSleep supports the formation of immunologicalmemory as evidencedbya stronger immune response tovac-
cination if subjects sleep during the subsequent night than if they stay awake. One mechanism underlying
this adjuvant-like action of sleep might be an enhanced homing of circulating naïve T cells to lymph nodes.
Indeed, compared tonocturnalwakefulness, sleep acutely lowers T cell counts in peripheral bloodduring the
early night,with theefﬂuxof these cells to lymphoid tissues possiblymediatedby sleep-associated release of
the mineralocorticoid aldosterone. We show here that blocking mineralocorticoid receptors by spironolac-
tone (200 mg, orally at 23:00 h and again at 4:00 h) in 11 healthymen enhances naïve T-helper cell counts in
blood during early nocturnal sleep. Effects in the same direction on naïve cytotoxic T cells and central mem-
oryT-helper cellswere less consistent. Spironolactonedidnot inﬂuenceT cell subsets notmigrating to lymph
nodes (i.e., CD62L effectormemory and effector T cells), or expression of CD62L and CXCR4. The typical cir-
cadiandecrease inT cell numbers in themorninghourswasnot affectedby theblockadeofmineralocorticoid
receptors, in linewith the view that this decrease ismainly due to activation of glucocorticoid receptors dur-
ing the circadian morning rise in cortisol. We assume that sleep-associated activation of mineralocorticoid
receptors at a time of low cortisol levels contributes to an enhanced redistribution of circulating naïve T-
helper cells to lymph nodes, as a mechanism that eventually promotes immunological memory formation.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Sleep deeply impacts adaptive immune functions. Speciﬁcally, it
has been shown that, compared with wakefulness, sleep on the
night after vaccination leads to a long lasting enhancement of anti-
gen-speciﬁc antibody and T-helper cell responses (Lange et al.,
2003, 2011). An adaptive immune response is initiated by antigen
presenting cells and naïve T cells that meet in secondary lymphoid
organs, with the number of naïve T cells recruited to lymphoid or-
gans essentially determining the size of the adaptive response, i.e.,
the number of effector T cells formed after vaccination (Pulendran
and Ahmed, 2006). Therefore, sleep might support the formation of
adaptive immunity by increasing migration of T lymphocytes to
lymph nodes.
In humans, numbers of T cells in peripheral blood ﬂuctuate
along the sleep-wake-cycle, which is due to combined inﬂuences
of the circadian system and sleep on cell trafﬁc. So, T cell numbers
peak during early night and show a strong cortisol-mediated de-
crease in the morning, which is not dependent on sleep as the
rhythm persists at large during 24 h of continuous wakefulnessendocrinology, University of
603; fax: +49 451 500 3640.
e).
-NC-ND license.(Born et al., 1997; Dimitrov et al., 2009). However, although overall
still higher than during daytime, numbers of T cells become re-
duced in the early night hours when subjects sleep compared to
the corresponding period when they remain awake. This shows
that early sleep fosters the extravasation of T cells and most likely
they are redirected to lymph nodes. Indeed, animal experiments
provide hints that sleep leads to an accumulation of lymphocytes
in lymph nodes (Dickstein et al., 2000; Zager et al., 2007). However,
the underlying mechanisms are not known. One potential candi-
date mediating such an inﬂuence of sleep on T cell migration is
the steroid hormone aldosterone, as this hormone has not only
been revealed to enhance the extravasation of lymphocytes in rats
(Miller et al., 1994) but is also released in a strongly sleep-depen-
dent fashion with highest pulse amplitudes and plasma levels dur-
ing sleep (Charloux et al., 1999, 2001). Aldosterone is produced by
the adrenal cortex and acts via the mineralocorticoid receptor (MR)
which is also found in lymphocytes (Armanini et al., 1985, 1988).
To examine the possible contribution of aldosterone to T cell
migration, here we tested effects of the MR antagonist spironolac-
tone on numbers of T cells and their subpopulations in peripheral
blood of healthy men during nocturnal sleep. We distinguished be-
tween CD4+ and CD8+ naïve, central memory, effector memory and
effector T cells and expected enhancing effects of spironolactone
speciﬁcally on CD62L+ naïve and central memory subsets, as these
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whereas CD62L effector memory and effector T cells do not
(von Andrian and Mackay, 2000). We also monitored CD62L
expression to elucidate if aldosterone promotes the extravasation
of T cells via increases in this adhesion molecule, which plays an
important role for the homing of T cells to lymph nodes (Butcher
and Picker, 1996; von Andrian and Mackay, 2000). Another pur-
pose of the study was to examine if the sleep-independent de-
crease in peripheral T cell numbers during early morning, which
is thought to reﬂect a redistribution of these cells to the bone mar-
row following the circadian cortisol rise (Dimitrov et al., 2009), is
mediated exclusively via glucocorticoid receptors (GR). To this
end, a second dose of spironolactone was administered at 4:00 h
to counteract the effects of the morning rise in cortisol on MR.2. Methods
2.1. Subjects
Eleven healthy men participated in this study (mean age,
20 years; range 18–27 years). All subjects had a normal nocturnal
sleep pattern, did not take any medications at the time of the
experiment and were nonsmokers. Acute and chronic illness was
excluded by medical history, physical examination, and routine
laboratory investigation. The men were synchronized by daily
activities and nocturnal rest. They had a regular sleep-wake
rhythm for at least 6 weeks before the experiments and no signs
of sleep disturbances, including apnea and nocturnal myoclonus.
All subjects spent one adaptation night in the laboratory in order
to become accustomed to the experimental setting. The study
was approved by the Ethics Committee of the University of Lübeck
(Lübeck, Germany) and all participants gave written informed con-
sent in accordance with the Declaration of Helsinki.2.2. Experimental design
During this double-blind, randomized study participants spent
two experimental nights in the sleep laboratory (in addition to
the adaptation night). On these nights, subjects arrived at the lab-
oratory at 21:00 h for preparing blood sampling and polysomno-
graphic recordings. Sleep was allowed between 23:00 h (lights
off) and 7:00 h. Subjects received either 200 mg of spironolactone
or placebo (orally) right before lights were turned off and a second
dosage of spironolactone or placebo, respectively, at approximately
4:00 h. The second dosage was given to assure a high plasma con-
centration of spironolactone during the second night half and early
morning known to be associated with high levels of the endoge-
nous MR ligands aldosterone and cortisol. To this end subjects in
both experimental conditions were gently awakened between
3:45 and 4:15 h, as soon as they had entered sleep stage 2. Awak-
enings from rapid eye movement (REM) sleep or slow wave sleep
(SWS) were avoided.
Blood was sampled ﬁrst at 23:00 h and then every 1.5 h until
9:30 h via an intravenous forearm catheter which was connected
to a long thin tube and enabled blood collection from an adjacent
room without disturbing the subject’s sleep. To prevent clotting,
approximately 700 mL of saline solution were infused during the
experimental period. Blood samples were always processed imme-
diately after sampling. Potential side effects of spironolactone were
evaluated in the morning by questionnaires. Standard polysomno-
graphic recordings were obtained to assure normal nocturnal
sleep. Blood pressure was assessed 30 min after awakening in the
morning. Both conditions for a subject were separated by 2 weeks
to assure clearance of the drug, and the order of conditions was
balanced across subjects.2.3. T cell subpopulations
Absolute counts of CD3+ total T cells, CD4+ T-helper cells, and
CD8+ cytotoxic T cells as well as their naïve (CD45RA+CD62L+), cen-
tral memory (CD45RACD62L+), effector memory (CD45RACD
62L), and (terminally differentiated) effector (CD45RA+CD62L)
subsets were determined by a ‘lyse no-wash’ ﬂow cytometry pro-
cedure. Brieﬂy, 50 lL of an undiluted blood sample was immuno-
stained with anti-CD3/APC-CY7, anti-CD8/PerCP, anti-CD4/PE-
CY7, anti-CD62L/FITC, anti-CD45RA/PE, and anti-CD184 (CXCR4)/
APC, in Trucount tubes (all from BD Biosciences, San Jose, CA). After
15 min of incubation at room temperature, 0.45 mL of ﬂuorescence
activated cell sorting (FACS) lysing solution (BD Biosciences) was
added followed by incubation for 15 min. Finally, samples were
mixed gently and at least 10 000 CD3+ cells were acquired on a
FACSCalibur using DIVA Software (BD Biosciences). The absolute
number of cells per lL blood was calculated using the following
formula: Cells/lL = (acquired cell events in the respective
gate)  (number of beads per tube)/((acquired bead events)
 (sample volume [lL])).
To study changes in relative quantity of CD184 (CXCR4) and
CD62L (L-selectin) on the cell subsets, the median ﬂuorescence
intensity (MFI) of the labeled anti-CD184-antibody and anti-
CD62L-antibody was analyzed.2.4. Hormone assays and sleep analyses
Samples for measuring hormone concentrations were kept fro-
zen at 70 C until assay. Cortisol in serum and adrenocorticotro-
pic hormone (ACTH) in plasma were measured using a commercial
assay (Immulite, Siemens Healthcare Diagnostics, Deerﬁled, USA).
Aldosterone was measured in serum, also using a commercial as-
say (DPC-Biermann, Bad Nauheim, Germany). Epinephrine and
norepinephrine were measured in plasma by standard high-perfor-
mance liquid chromatography. Sensitivity, intraassay and interas-
say coefﬁcients of variation were as follows: cortisol 0.2 lg/dL,
less than 10%; ACTH 9 pg/mL, less than 9.5%; aldosterone 11 pg/
mL, less than 16%; epinephrine 2 pg/mL, less than 6.5%; norepi-
nephrine 5 pg/mL, less than 6%.
Sleep stages were determined off-line from polysomnographic
recordings following standard criteria (Rechtschaffen and Kales,
1968). For each night, sleep onset (with reference to lights off at
23:00 h), total sleep time (sum of time spent in sleep stages 1, 2,
3, and 4 and REM sleep), and the time as well as percentage of total
sleep time spent in the different sleep stages were calculated. In
addition, we determined the time between awakening of subjects
around 4:00 h for the second administration of spironolactone or
placebo and falling asleep again. SWS was deﬁned by the sum of
stage 3 and 4 sleep.2.5. Statistical analyses
Analyses of variance (ANOVA) for repeated measurements were
calculated on T cell subpopulations (absolute counts, CXCR4
expression, CD62L expression) and hormones. Factors included
were ‘‘Condition’’ (spironolactone versus placebo), ‘‘Early/late’’
(23:00–3:30 h versus 5:00–9:30 h) and ’’Time’’ (reﬂecting the four
time points of measurements during the early and late night,
respectively). We included the factor ‘‘Early/late’’ since we ex-
pected the effects of spironolactone only during the early night,
when the impact of sleep on T cell migration is evident (see Sec-
tion 1). Degrees of freedom were corrected according to the Green-
house-Geisser procedure. In case of ANOVA effects, paired t tests
were analyzed at single time points. A p-value <0.05 was consid-
ered signiﬁcant. Data are presented as mean ± SEM.
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3.1. Absolute counts of T cell subpopulations
T cells were classiﬁed as CD4+ (T-helper) and CD8+ (cytotoxic) T
cells, and both of these subpopulations were further divided in
naïve, central memory, effector memory and effector T cells. The
absolute counts of all subpopulations with the exception of effector
CD4+ and effector CD8+ T cells showed a peak during the ﬁrst night
half (23:00–3:30 h) followed by a decline until the last blood sam-
pling at 9:30 h (F(1,10)P 9.68, p 6 0.01, for main effects of Early/
late and F(3,30)P 8.27, p 6 0.002 for Early/late  Time. Figs. 1
and 2).
Compared with placebo, administration of spironolactone sig-
niﬁcantly enhanced counts of CD4+ T cells and their naïve subpop-
ulation, with these effects concentrating on the early part of the
night. For both populations the Condition  Early/late  Time
interaction term revealed to be signiﬁcant (total CD4+ T cells:
F(3,30) = 3.50, p = 0.038; naïve CD4+ cells: F(3,30) = 3.41,
p = 0.048). Moreover, post hoc pairwise comparisons showed that
for both the total CD4+ population and the naïve CD4+ subset the
spironolactone induced increase in cell counts was most consistent
at 3:30 h (p = 0.003; 0.007, respectively).
Similar increases after spironolactone in cell numbers of total T
cells, central memory CD4+ and naïve CD8+ T cells did not reach sig-
niﬁcance in the ANOVA results (F(3,30) = 2.95, p = 0.061;
F(3,30) = 2.33, p = 0.107; F(3,30) = 2.78, p = 0.072, respectively, for
Condition  Early/late  Time;p = 0.010; 0.028; 0.066, respectively,
for post hoc pairwise comparisons at 3:30 h). All other subpopula-
tions (total CD8+ T cells, centralmemoryCD8+ T cells, and all CD62L
subsets) were not inﬂuenced by spironolactone (Figs. 1 and 2).
3.2. Expression of CXCR4 and CD62L
Spironolactone did not inﬂuence the expression of CXCR4 on
any subpopulation, nor did it affect the time course of CXCR4
expression. The same was true for the expression of CD62L (data
not shown). CXCR4 expression was highest in the naïve and central
memory subpopulations of CD4+ and CD8+ T cells, and showed a
decline over time during the ﬁrst night half reaching lowest levelsFig. 1. Circulating total T cells, T-helper cells and cytotoxic T cells. Mean (±SEM) of
total T cells (CD3+), T-helper cells (CD4+) and cytotoxic T cells (CD8+). n = 11.
⁄⁄p < 0.01, for pairwise comparisons between spironolactone and placebo. See text
for ANOVA results. Gray area indicates sleep time.around 3:30 h. Thereafter, expression continuously increased dur-
ing the late night on naïve CD4+ and CD8+ T cells as well as on cen-
tral memory and effector memory CD4+ T cells (F(3,30)P 5.56,
p 6 0.012, for respective Time and Early/late  Time effects, data
not shown).
3.3. Hormones
Plasma cortisol showed the typical circadian variation peaking
at the time of awakening (Fig. 3). Levels of aldosterone and ACTH
showed a similar time course, both peaking at 8:00 h. Spironolac-
tone enhanced cortisol levels at 9:30 h compared with the placebo
condition (F(1,10) = 7.72, p = 0.020, for Condition  Early/late
interaction; p = 0.026 for post hoc pairwise comparison), whereas
ACTH levels were not affected by the MR blocker. This pattern is
well in line with previous studies (Dodt et al., 1993; Young et al.,
1998) which likewise found that MR antagonists increased cortisol
in the absence of changes in ACTH. Increases in aldosterone levels
after spironolactone administration did not reach signiﬁcance
(F(3,30) = 3.00, p = 0.073, for Condition  Early/late  Time inter-
action; p = 0.033 and 0.093 for post hoc pairwise comparisons at
3:30 and 6:30 h, respectively). Noradrenaline and adrenaline were
not inﬂuenced by spironolactone. We also calculated a ratio be-
tween aldosterone and cortisol because cortisol has an inﬂuence
on lymphocyte migration which could compete with that of aldo-
sterone. This aldosterone/cortisol ratio was highest during the ﬁrst
half of the night followed by a continuous decrease that leveled out
around 6:30 h. However, the ratio was not inﬂuenced by spirono-
lactone (Fig. 3).
3.4. Sleep, blood pressure and side effects
Subjects slept normally in both conditions with a predominance
of SWS during the ﬁrst night half and of REM sleep in the second
night half, reﬂecting a sleep architecture typical for laboratory con-
ditions (total sleep time: 436.9 ± 3.84 min, time in sleep stage 1:
35.9 ± 3.19 min, sleep stage 2: 234.9 ± 8.14 min, SWS: 80.4
± 5.76 min, REM sleep: 85.7 ± 4.70 min). Time between awakening
of subjects around 4:00 h for the second administration of spirono-
lactone or placebo and falling asleep again was on average
16.3 ± 3.2 min (collapsed across conditions). In line with a previous
report (Steiger et al., 1993), spironolactone did not inﬂuence any of
the sleep parameters measured. There was also no difference in
blood pressure between both conditions. Spironolactone produced
no side effects and subjects who were all blind to the condition
were also not able to correctly indicate whether they received pla-
cebo or spironolactone.
4. Discussion
Following ﬁndings that sleep enhances the immune response to
vaccination (Lange et al., 2003, 2011), here we asked whether such
an effect might partly derive from an aldosterone mediated facili-
tation in the homing of circulating naïve T cells to lymph nodes.
Consistent with this view we found that acute blockade of the
MR in sleeping humans after administration of spironolactone,
compared with a placebo condition, enhances naïve T-helper cell
counts in peripheral blood during the early night. This ﬁnding
reﬂecting a diminished extravasation of these T cells is well in line
with ﬁndings in adrenalectomized rats exhibiting a decrease in T-
helper cell numbers in blood after 7 days of aldosterone treatment
(Miller et al., 1994). Also, aldosterone appeared to acutely counter-
act stress-induced increases in lymphocyte numbers in adrenalec-
tomized rats (Dhabhar et al., 1996), altogether supporting the view
that aldosterone via activating MR basically promotes extravasa-
tion of T-helper cells.
Fig. 2. Circulating T cell subsets. Mean (±SEM) of naïve, central memory, effector memory and effector CD4+ (left) and CD8+ (right) T cells. n = 11. ⁄⁄p < 0.01, ⁄p < 0.05,
(⁄)p < 0.10 for pairwise comparisons between spironolactone and placebo. See text for ANOVA results. Gray area indicates sleep time.
Fig. 3. Cortisol, aldosterone and ACTH concentrations and aldosterone/cortisol ratio. Data presented as means (±SEM). n = 11. ⁄p < 0.05, (⁄)p < 0.10 for pairwise comparisons
between spironolactone and placebo. See text for ANOVA results. Gray area indicates sleep time.
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population showed a robust increase after spironolactone, similar
increases in central memory CD4+ and naïve CD8+ T cells were less
consistent. Indeed, a lower sensitivity of CD8+ than CD4+ T cells to
mineralocorticoid effects is in keeping with previous ﬁndings in
rats (Miller et al., 1994) where aldosterone likewise reduced only
circulating CD4+ but not CD8+ T cells. Also, the decrease in lympho-
cyte counts induced by sleep is more pronounced in CD4+ than
CD8+ T cells (Born et al., 1997), and the basal clearance rate of
CD4+ T cells from blood into lymph nodes is reported to be twiceas high as that of CD8+ T cells (Ottaway and Husband, 1992). Inter-
estingly, the magnitude and time-course of the spironolactone-in-
duced increase in T-helper cell counts during early sleep was
considerably similar to that seen in humans when staying awake
the night (Born et al., 1997; Lange et al., 2010), suggesting that noc-
turnal blocking of MR mimics the effects of nocturnal wakefulness
on T-helper cell numbers.
The selective effect of spironolactone on the naïve subset of T-
helper cells is in accordance with results from earlier experiments
indicatingdifferential sensitivityof cell subpopulations toendocrine
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mediator of T cell homing to lymph nodes, our ﬁnding that only
CD62L+ T cells were inﬂuenced by spironolactone well ﬁts the view
that sleep-associated aldosterone release mediates a preferential
accumulation of naïve T cells in lymphnodeswhere these cells serve
the generation of a primary antigen-speciﬁc immune response to
infection.
Compared with previous studies that revealed highest pulse
amplitudes of aldosterone release as well as highest aldosterone
plasma levels during sleep (Charloux et al., 1999, 2001), aldoste-
rone levels in the present study were higher in the morning than
during the night. However, our blood sampling rate (1/1.5 h) was
too low to cover the pulsatile character of nocturnal aldosterone
release. The steep morning increase in aldosterone likely reﬂects
an orthostatic response as our subjects got up at 7:00 h and then
remained in an upright position.
Spironolactone and its active metabolites reach highest plasma
concentration 2 to 5 h after oral administration (Gardiner et al.,
1989; Jankowski et al., 1996), which explains that the increasing
effect of spironolactone on T cell counts did not peak until
3:30 h. Interestingly the effect ceased towards the morning
although aldosterone levels were increased at that time. However,
this rise in aldosterone was paralleled by the circadian morning
rise in cortisol, which is thought to mediate an extravasation and
redistribution of lymphocytes to the bone marrow via activation
of GR (Dimitrov et al., 2009; Fauci, 1975; Ottaway and Husband,
1992). This effect of cortisol on T cell migration, which reﬂects a
circadian component and is overall not dependent on sleep, is of
much higher magnitude compared to the impact of early sleep
on peripheral T cell numbers. Thus, any increasing effect of an
MR blockade on cell counts in the morning would be masked by
the potent cortisol-induced redistribution of T cells to the bone
marrow. Additionally, cortisol has been shown to interfere with
the migration of lymphocytes from peripheral blood into lymph
nodes (Ottaway and Husband, 1992; Sackstein and Borenstein,
1995), an effect that is also expected to interfere with an aldoste-
rone-mediated redistribution of T cell to lymph nodes during the
morning rise in cortisol. Taken together, our ﬁnding that effects
of spironolactone faded with increasing cortisol concentrations in
the morning, suggests that the regulatory inﬂuence of aldosterone
on T cell counts emerges only in the presence of low cortisol levels,
possibly linked to a reduced activation of GR. Indeed, although
both cortisol and aldosterone levels increased during the morning
hours, the ratio between aldosterone and cortisol was much higher
during the early night, when the effects of spironolactone on T cell
counts were apparent. This tempts to speculate that rather than
MR activation per se, the balance between MR and GR activation
is more crucial for the regulation of T cell migration.
On the other hand, the effect of spironolactone fading in the
morning hours can be taken to exclude that MR signaling is in-
volved in the prominent circadian decline in T cell numbers at that
time. This decline in T cells was paralleled not only by an increase
in cortisol but also in CXCR4 expression, i.e., a pattern in line with
the view derived from previous studies that cortisol via activation
of GR induces CXCR4 expression which in turn accelerates the
migration of T cells, presumably into the bone marrow (Dimitrov
et al., 2009; Fauci, 1975; Okutsu et al., 2005). GR and MR can form
heterodimers thereby increasing the functional diversity of these
receptors (Liu et al., 1995; Nishi et al., 2004; Trapp et al., 1994).
The fact that spironolactone did neither affect CXCR4 expression
nor the decrease in blood T cell counts in the morning shows that
this pattern is GR driven, and does not require concomitant activa-
tion of MR.
Of note, in the absence of the enzyme 11b-hydroxysteroid
dehydrogenase 2 cortisol binds MR with even higher afﬁnity than
GR (Krozowski et al., 1999; Rupprecht et al., 1993; Zhang et al.,2005). Estimates from animal studies indicate that during the cir-
cadian nadir of glucocorticoid levels about 50 per cent of MR are
occupied by endogenous corticosteroids (Kalman and Spencer,
2002). Therefore, the increasing effect of spironolactone on naïve
T cell counts might basically stem also from a blockade of low cor-
tisol levels acting on the MR. However, in humans, there is evi-
dence for a threefold higher afﬁnity of lymphocytic MR for
aldosterone than cortisol (Armanini et al., 1985), making it unlikely
that cortisol substantially contributes to MR mediated T cell traf-
ﬁcking during early nocturnal sleep. Also, an unspeciﬁc mediation
of the effects via non-lymphocytic MR seems unlikely, as the effect
was cell-subset speciﬁc, with no impact of spironolactone on
CD62L T cells, and we did not observe any effects on blood pres-
sure or sleep architecture, nor did the subjects report any side ef-
fects. Though unlikely, it cannot be fully ruled out that non-MR
mediated effects of spironolactone, like a down-regulation of IL-2
production (Sonder et al., 2006), added to the observed increase
in circulating T helper cells. Testing with more speciﬁc MR antag-
onists or agonists might help to resolve this issue in future studies.
Indeed, preliminary studies of ours revealed a distinct decrease in
circulating naïve T cells following administration of the MR agonist
ﬂudrocortisone, overall conﬁrming the major role of MR in regulat-
ing T cell extravasation.
We suspected that MR signaling impacts migration of naïve T-
helper cell counts through increasing expression of the adhesion
molecule CD62L. This was not conﬁrmed as spironolactone did
not change CD62L expression on any of the T cell subsets. This does
not exclude that MR signaling might increase the afﬁnity of CD62L
for its ligand which was not tested here. Migration of T cells to
lymph nodes also involves activation of the chemokine receptor
CCR7 as well as the integrin LFA-1, changes in the expression or
afﬁnity of which represent alternative pathways that can mediate
facilitating effects of MR signaling on T cell homing. It has recently
been shown that aldosterone increases expression of the LFA-1 li-
gand ICAM-1 on endothelial cells resulting in an enhanced adhe-
sion of leukocytes to the vessel walls (Caprio et al., 2008; Krug
et al., 2007). However, such effect per se would not sufﬁciently ex-
plain why the effect of MR blockade was speciﬁc for the naïve T cell
subset, which is known to show only moderate LFA-1 expression in
comparison to the other subpopulations (Dimitrov et al., 2010).
The mechanisms underlying this selectivity, hence, need to be clar-
iﬁed in further studies.
In conclusion, we have shown that the blockade of MR by spiro-
nolactone enhances the number of circulating naïve T-helper cells
during early sleep, whereas the prominent circadian decrease in T
cell counts in the morning remained unaffected, which is in line
with the view that this circadian decrease in T cells is solely driven
by cortisol-induced GR activation. We propose that MR signaling
during early nocturnal sleep, on top of these circadian changes,
ﬁne-tunes the redistribution and homing of naïve T helper cells
to lymph nodes, thereby eventually supporting the formation of
immunological memory.Conﬂict of interest statement
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